Regeneron slips as Raymond James downgrades on Eylea concerns

Digital Eye Wave Lines Stock Background

Sharamand/iStock via Getty Images

Regeneron (NASDAQ:REGN) dropped ~2% pre-market Wednesday after Raymond James downgraded the pharma giant to Underperform from Market Perform, citing concerns on the future of its eyecare franchise led by anti-VEGF agent Eylea.

Regeneron (REGN) surged in

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.